MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-14-2025
OptiNose Book Value 2011-2026 | OPTN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value OptiNose
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.6 M | -56.6 M | -21.8 M | 6.79 M | 61.6 M | 119 M | 154 M | -3.84 M | -27.1 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | -86.6 M | 16.2 M |
Quarterly Book Value OptiNose
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61.4 M | -40.4 M | -41.1 M | -42.9 M | -99.2 M | -86.6 M | -77.6 M | -69.7 M | -73.8 M | -56.6 M | -73.4 M | -60.8 M | -44.9 M | -21.8 M | -51.5 M | -37.1 M | -16.7 M | 6.79 M | 6.79 M | 6.79 M | 6.79 M | 61.6 M | 61.6 M | 61.6 M | 61.6 M | 119 M | 119 M | 119 M | 119 M | 154 M | 154 M | 154 M | 154 M | 17 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | -99.2 M | 12.7 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
1.71 B | $ 2.68 | 3.08 % | $ 1.37 B |  Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 4.06 | 4.1 % | $ 57.1 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
-82 M | $ 5.63 | 1.53 % | $ 2.05 B | Canada |
 |
Jupiter Wellness
JUPW
|
35 M | - | - | $ 33.6 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.19 | -2.87 % | $ 128 M | Canada |
 |
Harrow Health
HROW
|
52.1 M | $ 39.7 | 2.45 % | $ 1.46 B | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.45 | 0.7 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 2.35 | 0.86 % | $ 309 M | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 5.3 | -0.19 % | $ 342 M | USA |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.51 | -1.31 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.03 | -0.74 % | $ 411 M | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 24.51 | -3.35 % | $ 1.13 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 1.01 | - | $ 4.36 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
94 M | $ 18.04 | 0.11 % | $ 116 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 7.92 | -3.65 % | $ 693 M | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 7.21 | -0.55 % | $ 285 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 1.14 | -36.67 % | $ 1.41 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tilray
TLRY
|
3.33 B | $ 6.75 | -2.74 % | $ 4.17 B | Canada |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 1.02 | -2.86 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Veru
VERU
|
32.3 M | $ 2.32 | 0.43 % | $ 313 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 14.59 | -1.08 % | $ 17.5 B | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.39 | 3.35 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
115 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
37 M | $ 0.87 | 1.99 % | $ 31.3 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
22.7 M | $ 0.61 | 1.65 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
26.9 M | $ 2.19 | 0.46 % | $ 25.3 M | USA |